漱玉平民(301017) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss for 2024 between 120 million and 220 million yuan, compared to a profit of 133.06 million yuan in the same period last year [3]. - The expected loss excluding non-recurring items is projected to be between 110 million and 210 million yuan, down from a profit of 126.88 million yuan in the previous year [3]. - A preliminary assessment indicates a potential goodwill impairment of approximately 30 million yuan, which significantly impacts the annual performance [6]. - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the 2024 annual report [4][7]. Market and Operational Challenges - The overall growth rate of pharmaceutical categories has slowed, with a structural decrease in the sales proportion of "four categories" drugs and health products due to changes in medical insurance policies [5]. - Increased operational costs are attributed to the expansion of the logistics system, with distribution centers established in multiple provinces, impacting short-term profitability [6]. Strategic Initiatives - The company plans to enhance its logistics and distribution capabilities, focusing on franchise and distribution business development to improve revenue and profitability [6].